Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Citius Pharmaceuticals News

    0,7555 € -6,44% -0,052 €
    12:43:08 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2DXS0
    ISIN: US17322U2078
    US-Symbol: CTXR
    Typ: Aktie

    Citius Pharmaceuticals News

    11.04.24 - PR Newswire
    Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
    Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma PR Newswire
    04.04.24 - PR Newswire
    Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
    Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference PR Newswire
    22.03.24 - PR Newswire
    Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
    Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics? PR Newswire
    18.03.24 - PR Newswire
    Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-...
    07.03.24 - PR Newswire
    Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
    Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program PR Newswire
    26.02.24 - PR Newswire
    Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration
    Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration PR Newswire
    23.02.24 - PR Newswire
    Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
    Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences PR Newswire
    14.02.24 - PR Newswire
    Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
    Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update PR Newswire
    14.02.24 - PR Newswire
    Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell ...
    23.01.24 - PR Newswire
    Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
    Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors PR Newswire
    02.01.24 - PR Newswire
    Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters
    Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters PR Newswire
    02.01.24 - PR Newswire
    Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
    Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update PR Newswire
    09.11.23 - PR Newswire
    Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
    Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 PR Newswire
    31.10.23 - PR Newswire
    Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
    Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor PR ...
    24.10.23 - PR Newswire
    Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
    Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. PR Newswire
    18.09.23 - PR Newswire
    Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
    Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 PR Newswire
    13.09.23 - PR Newswire
    Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
    Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir PR Newswire
    08.09.23 - PR Newswire
    Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
    Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ PR ...
    06.09.23 - PR Newswire
    Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
    Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 PR Newswire
    14.08.23 - PR Newswire
    Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
    Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update PR Newswire

    Newssuche

    Videos

    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »